Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate
Bristol-Myers Squibb Co (BMY.N) and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug.
U.S. approval of Biogen Alzheimer’s drug sends shares soaring, hailed as ‘big day” for patients
U.S. regulators on Monday approved Biogen Inc’s (BIIB.O) aducanumab as the first treatment to attack a likely cause of Alzheimer’s disease despite controversy over whether the clinical evidence proves the drug works, sending its shares soaring.
